Tramadol Overdose: Signs and Symptoms, Why Tramadol Is More Dangerous Than People Assume, the Seizure and Serotonin Syndrome Risks, and What Heavy Drinking Adds to the Picture

A clinician’s guide to tramadol overdose, the signs and symptoms, why tramadol is more dangerous than its reputation as a mild opioid suggests, the distinctive seizure and serotonin syndrome risks that distinguish tramadol overdose from other opioid overdoses, the lethal combination with alcohol and other CNS depressants, and the role of naloxone in management.

Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.

Tramadol overdose occurs when a person takes more tramadol than their body can safely tolerate. Signs and symptoms include severe drowsiness, slow or shallow breathing, pinpoint pupils, slurred speech, impaired coordination, low blood pressure, and in severe cases unresponsiveness, seizures, and respiratory arrest. Tramadol overdose differs from typical opioid overdose in two important ways. First, tramadol has substantial serotonergic activity, which means tramadol overdose can produce serotonin syndrome with agitation, tremor, clonus, hyperthermia, and autonomic instability in addition to the typical opioid features. Second, tramadol lowers the seizure threshold, and tramadol overdose can produce seizures even at relatively modest doses, particularly when combined with other medications that affect seizure threshold. The lethal dose of tramadol alone is generally considered to be above 3 grams in opioid-naive adults, but fatal outcomes have been reported at much lower doses, particularly when combined with alcohol, benzodiazepines, sleeping pills, antidepressants, or other substances that amplify either the respiratory depression, the seizure risk, or the serotonin syndrome risk. Naloxone (Narcan) reverses the opioid component of tramadol overdose but does not address the seizures or serotonin syndrome, which require their own management.

What is a tramadol overdose?

Tramadol overdose occurs when a person takes more tramadol than their body can safely tolerate, alone or in combination with other substances. Tramadol is a prescription painkiller used for moderate to severe pain, marketed under brand names including Tramal, Zydol, Ultram, Ralivia, and Tramadex, and available in immediate-release and extended-release formulations. The medication was originally promoted in the 1990s as a relatively safe non-controlled opioid with low addiction potential, an assessment that proved overly optimistic; tramadol was rescheduled as a Schedule IV controlled substance in the United States in 2014 and is controlled in most other jurisdictions.

Tramadol acts through two pharmacological mechanisms that make its overdose picture different from pure opioids. First, tramadol is a weak mu-opioid receptor agonist; its active metabolite O-desmethyltramadol (M1), formed by the cytochrome P450 enzyme CYP2D6, binds the mu receptor about 200 times more strongly than tramadol itself. Second, tramadol inhibits the reuptake of serotonin and noradrenaline, similar to the SNRI class of antidepressants. The dual mechanism gives tramadol overdose features that other opioid overdoses do not have, including a substantial risk of serotonin syndrome and a markedly lowered seizure threshold.

Tramadol overdose can be intentional (a deliberate self-harm event) or accidental. Accidental overdose can come from taking too much for relief from pain, from misjudging a dose under the influence of alcohol or other medications, from CYP2D6 ultra-rapid metaboliser status producing unexpectedly strong effects, from drug interactions that raise tramadol levels, or from the polypharmacy patterns that are common in patients with chronic pain. The substance’s reputation as a relatively safe opioid contributes to the accidental overdose pattern; patients and prescribers underestimate the danger because the drug is positioned as gentler than oxycodone or morphine.

The clinical picture of tramadol overdose is more complex than that of pure opioid overdose because of the three potentially co-existing problems: opioid effects (respiratory depression, sedation, miosis), seizures (which can occur at relatively modest doses), and serotonin syndrome (which can develop especially with co-administration of serotonergic medications). The combination of these three features in any individual patient depends on the dose, the patient’s CYP2D6 metaboliser status, the other substances involved, and individual factors including seizure history and serotonergic medication use.

Signs and symptoms of tramadol overdose

The opioid features of tramadol overdose develop over the hour or two after ingestion and include severe drowsiness, slurred speech, impaired coordination, slow or shallow breathing, low blood pressure, slow heart rate, miosis (pinpoint pupils that do not respond well to light), reduced bowel sounds, and in severe cases unresponsiveness, profound respiratory depression, and respiratory arrest. The opioid features are similar to those of overdose with other opioids and respond to naloxone. The respiratory depression is the lethal component; the brainstem respiratory drive is suppressed beyond the body’s capacity to maintain adequate breathing, oxygen levels fall, and hypoxic injury or death follows within minutes if not reversed.

Seizures are one of the most distinctive features of tramadol overdose and can occur at doses much lower than those producing severe opioid features. Tramadol-induced seizures typically develop within 24 hours of the overdose, are usually generalised tonic-clonic seizures, and can occur in patients with no prior seizure history. The seizure risk is dose-dependent and is substantially elevated in patients on other medications that lower the seizure threshold (some antidepressants including bupropion, fluoroquinolone antibiotics, antipsychotics, theophylline, certain antimalarials), in patients with prior seizure history, in patients with electrolyte derangement, in patients with sleep deprivation, and in patients consuming alcohol. Tramadol-induced seizures may occur as single events or as recurrent seizures requiring active management with benzodiazepines.

Serotonin syndrome features can develop in tramadol overdose, particularly when other serotonergic medications are also present. Serotonin syndrome is a potentially fatal condition caused by excessive serotonergic activity in the central nervous system. The clinical presentation includes mental status changes (agitation, confusion, restlessness, hallucinations), autonomic instability (sweating, fever, tachycardia, blood pressure swings, mydriasis or dilated pupils, diarrhoea), and neuromuscular abnormalities (tremor, clonus including ocular clonus, hyperreflexia, muscle rigidity, akathisia). Severe cases progress to hyperthermia above 40 degrees Celsius, seizures, rhabdomyolysis, and death. The Hunter Criteria are the standard diagnostic tool and emphasise clonus and rigidity as the most specific features.

The classic teaching is that opioid overdose produces miosis (pinpoint pupils) while serotonin syndrome produces mydriasis (dilated pupils). In tramadol overdose, the patient may have features of both, and the pupil findings can be confusing. The mental state can also be mixed; the patient may have the sedation of opioid overdose but with overlying agitation or restlessness from serotonin syndrome features. Recognising the combined picture is important for management because the supportive care for each component differs and the wrong assumption can produce poor outcomes.

Cardiovascular features of tramadol overdose include tachycardia (often from serotonergic activity rather than typical opioid effect), hypotension, and rarely QT prolongation that can produce torsades de pointes. The cardiovascular features are usually mild but can be substantial in severe overdoses, in elderly patients, in patients with cardiac disease, and in patients on other QT-prolonging medications. Cardiac monitoring is part of standard emergency department management.

Why tramadol is more dangerous than people assume

Tramadol was originally marketed as a relatively safe opioid with low addiction potential and low overdose risk. The medication was non-controlled in many jurisdictions when it was first launched and remained non-controlled in the US until 2014. The marketing positioned tramadol as suitable for moderate pain in patients who needed something stronger than NSAIDs but who should not have a stronger opioid. The clinical picture that emerged with widespread use has been substantially more concerning than the original marketing suggested, and the medication is now treated with much more clinical caution.

The first reason tramadol is more dangerous than people assume is the seizure risk. Tramadol lowers the seizure threshold substantially, and seizures can occur at therapeutic doses in vulnerable patients, at doses just above therapeutic in patients on interacting medications, and at relatively modest overdose levels. The seizure risk is one of the more clinically important features that distinguishes tramadol from other opioids and is one of the most common reasons tramadol patients end up in emergency departments. Patients who would have survived a similar overdose of oxycodone or hydrocodone without major complications can develop status epilepticus from a tramadol overdose.

The second reason is the serotonergic activity and the serotonin syndrome risk. Tramadol is increasingly used alongside SSRIs, SNRIs, and other serotonergic medications, and the combination produces clinically significant serotonin syndrome risk that other opioids do not have. The risk is highest when tramadol is combined with monoamine oxidase inhibitors (which can produce severe and life-threatening serotonin syndrome), but combinations with SSRIs, SNRIs, tricyclic antidepressants, triptans, lithium, St John’s wort, and some illicit drugs can also produce serotonin syndrome. The number of patients on serotonergic medications has grown substantially in recent decades, which has expanded the population at risk for tramadol-related serotonin syndrome.

The third reason is the CYP2D6 variability. CYP2D6 is the enzyme that converts tramadol to its more potent metabolite O-desmethyltramadol. CYP2D6 activity varies substantially between individuals based on genetic polymorphisms; approximately 5 to 10 percent of European-ancestry populations are poor metabolisers (less analgesia but also less euphoria from tramadol), and approximately 1 to 5 percent are ultra-rapid metabolisers (stronger and faster effects with elevated risk of respiratory depression). The ultra-rapid metaboliser phenotype has been associated with several published case reports of fatal respiratory depression from therapeutic doses of tramadol. The patient cannot easily predict their own CYP2D6 status without testing, which is not done routinely.

The fourth reason is the addictive potential that was underestimated in the original marketing. Tramadol produces opioid use disorder in regular users, particularly at higher doses or with longer duration of use. The combination of the opioid effect and the serotonergic mood effect produces a subjective experience that some patients find more reinforcing than a pure opioid. Tramadol use disorder is increasingly recognised in addiction medicine and has features distinct from the typical oxycodone or hydrocodone use disorder picture. Patients can become dependent on tramadol with persistent use and experience challenging withdrawal that includes both the typical opioid features and an additional antidepressant-discontinuation-like syndrome.

Tramadol overdose with alcohol: the multiplied risk

Combining tramadol with alcohol is one of the more dangerous prescribing scenarios in clinical practice and is responsible for a substantial fraction of fatal tramadol overdoses. The risk has multiple components. The respiratory depression of tramadol is amplified by alcohol’s additive central nervous system depressant effect. The seizure risk of tramadol is amplified by alcohol because alcohol withdrawal lowers the seizure threshold and because acute heavy drinking can produce its own electrolyte derangements. The serotonergic effects of tramadol are altered by alcohol’s effects on serotonin signalling. The combination is substantially more dangerous than either substance alone, and the dose at which a fatal outcome can occur is lower than for either alone.

The pattern of heavy drinking combined with daily tramadol use is one that addiction medicine practitioners see frequently. Patients prescribed tramadol for chronic pain often have a longstanding heavy drinking pattern that pre-dated the prescription. The opioid effect of tramadol is amplified by alcohol; the patient consumes both the prescribed tramadol and the usual evening drinking, and the combination produces deeper sedation, more cognitive impairment, and elevated risk of fatal respiratory depression. The pattern often persists for months or years before a specific event (a near-overdose, a seizure, a fall while heavily intoxicated, a family confrontation) forces recognition.

The combined tramadol-alcohol pattern is dangerous in another way that pure tramadol use is not: heavy drinking on its own raises the seizure threshold (because alcohol enhances GABA activity acutely) but produces seizures during withdrawal periods. A heavy drinker who is taking tramadol regularly and who reduces or stops drinking, even briefly, can develop seizures from the combination of alcohol withdrawal and tramadol’s seizure-threshold-lowering effect. The combined risk during withdrawal periods is substantial and is one of the reasons medical detox in a clinical setting is essential for patients with combined dependence.

Patients who take tramadol while heavily drinking are also at elevated risk of accidents and injuries during the intoxicated state. Falls, motor vehicle accidents, accidental overdose from taking additional tramadol while too intoxicated to remember the previous dose, and self-harm during the disinhibited state all become more common. The pattern is particularly dangerous because the medications and the alcohol can both impair memory formation, so the patient may not recall the events that led to a particular crisis and may continue the pattern that produced it.

Other dangerous combinations

Tramadol combined with benzodiazepines (Xanax, Valium, Ativan, Klonopin) is one of the most lethal combinations in addiction medicine. The combined respiratory depression is the lethal mechanism, with the additive effect substantially greater than either substance alone. The FDA placed a black-box warning on the concurrent prescribing of benzodiazepines and opioids in 2016, reflecting the seriousness of this risk. Patients on both medications need explicit warnings, dose adjustments, and ongoing assessment for problematic patterns.

Tramadol combined with other CNS depressants (sleeping pills like Ambien and Lunesta, gabapentinoids like gabapentin and pregabalin, antihistamines like diphenhydramine and doxylamine, muscle relaxants like cyclobenzaprine) produces similar additive respiratory depression. The combinations are sometimes intentional (the patient taking sleeping pills for the sleep effect alongside tramadol for pain) and sometimes inadvertent (the patient not aware that an over-the-counter sleep aid containing diphenhydramine is itself a CNS depressant).

Tramadol combined with serotonergic medications carries the serotonin syndrome risk. The highest-risk combinations are with MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline at higher doses, linezolid, methylene blue), which are absolute contraindications. Combinations with SSRIs (sertraline, fluoxetine, paroxetine, escitalopram, citalopram), SNRIs (venlafaxine, duloxetine, desvenlafaxine), tricyclic antidepressants, triptans, lithium, and St John’s wort are not contraindicated but require careful monitoring. The risk is highest at the start of new combinations and at dose escalations. Patients should disclose all medications including supplements when starting tramadol.

Tramadol combined with other opioids (oxycodone, hydrocodone, morphine, fentanyl, heroin) produces additive opioid effects with elevated risk of respiratory depression. Tramadol combined with stimulants (cocaine, methamphetamine, amphetamine) can produce dangerous cardiovascular effects and reduces the apparent sedation of the tramadol without reducing the respiratory depression, leading to overdose at doses that would otherwise produce obvious warning signs. Tramadol combined with cannabis amplifies the cognitive impairment and can produce cardiovascular effects in vulnerable patients.

The CYP3A4 and CYP2D6 enzyme interactions are also clinically relevant. Strong CYP3A4 inhibitors (ritonavir, ketoconazole, clarithromycin, erythromycin, grapefruit juice in large amounts) raise tramadol levels and prolong its effects. CYP3A4 inducers (carbamazepine, rifampicin, St John’s wort, phenytoin) reduce tramadol levels and may reduce analgesia, sometimes prompting patients to escalate the dose. CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) reduce the conversion to the active M1 metabolite, which paradoxically can reduce analgesia while increasing the parent tramadol concentration and its serotonergic effects.

Emergency management of tramadol overdose

Emergency management of suspected tramadol overdose follows the general principles of opioid overdose management with several tramadol-specific additions. The first step is to call emergency services. The second step is to support breathing and prevent aspiration; place the person on their side, monitor breathing, and provide rescue breathing if breathing stops. The third step is to administer naloxone if available; naloxone reverses the opioid component of tramadol overdose and is the standard first-line antidote. Naloxone does not reverse the seizure or serotonin syndrome components, but reversing the respiratory depression is the most acute priority.

Naloxone for tramadol overdose follows the same dosing as for other opioid overdoses: 4 mg intranasally (Narcan) or 0.4 to 2 mg intramuscularly or intravenously, with repeat doses every 2 to 3 minutes if the person does not respond or relapses. Tramadol’s relatively long half-life (about 6 to 7 hours, with the active metabolite somewhat longer) means that naloxone (half-life of about 1 hour) may need to be redosed as the naloxone wears off and the tramadol is still active. Patients given naloxone for tramadol overdose require continued monitoring for at least several hours, often with repeat dosing if needed.

Seizure management is a tramadol-specific consideration. Seizures during tramadol overdose are typically managed with benzodiazepines (lorazepam 4 mg IV, midazolam 10 mg IM, or diazepam 10 mg IV), which raise the seizure threshold and terminate active seizures. Patients with recurrent or prolonged seizures may require additional anti-epileptic medications or intubation for airway protection. Naloxone may paradoxically increase seizure risk in tramadol overdose by reversing the opioid component that was partially suppressing the serotonergic and seizure-producing effects, so naloxone dosing should be done thoughtfully with seizure precautions in place.

Serotonin syndrome management includes discontinuation of serotonergic medications, supportive care (cooling, fluids, monitoring), benzodiazepines for agitation and muscle rigidity, and in severe cases cyproheptadine (a serotonin antagonist) or other specific interventions. Severe hyperthermia (above 40 degrees Celsius) requires aggressive cooling and may require intubation and paralysis to control muscle activity. Most cases of serotonin syndrome resolve within 24 to 48 hours of removing the precipitating medications and providing supportive care.

Hospital management of tramadol overdose typically includes observation for at least 12 to 24 hours, sometimes longer for patients with combined ingestions, severe seizures, or serotonin syndrome features. Cardiac monitoring, electrolyte management, intravenous fluids, and seizure prophylaxis are standard. Psychiatric evaluation is appropriate after any intentional overdose and is often appropriate after accidental overdoses to assess for underlying substance use disorder and to plan ongoing treatment. Patients with established opioid use disorder are referred for addiction treatment, including consideration of medication-assisted treatment with buprenorphine or methadone.

When tramadol use has become more than occasional

Patterns that suggest tramadol use has become more than occasional include taking more than prescribed, taking it for reasons other than pain (anxiety, sleep, mood, the antidepressant-like effect), running out before the next prescription is due, doctor shopping for additional prescriptions, combining with alcohol or other substances, experiencing withdrawal symptoms between doses, and being unable to reduce or stop the medication. The withdrawal from tramadol has the typical opioid component (muscle aches, sweating, runny nose, abdominal cramping, anxiety) plus an additional antidepressant-discontinuation-like syndrome (brain zaps, intense anxiety, depressed mood) that some patients find particularly difficult to tolerate.

The combination of tramadol dependence and heavy drinking is one of the more challenging clinical scenarios in addiction medicine. Patients in this pattern often have substantial medical complications (liver harm from the alcohol, the seizure risk from tramadol withdrawal during alcohol withdrawal periods, the cumulative respiratory depression risk), substantial psychiatric complications (depression, anxiety, the discontinuation syndrome from tramadol), and substantial social and functional impairment. Treatment requires medical detox in an inpatient setting because of the combined seizure risk, followed by integrated addiction medicine treatment for both substances.

Treatment options for tramadol dependence include medical detox with structured taper (typically cross-titrated to a longer-acting opioid such as buprenorphine to smooth the discontinuation), medication-assisted treatment with buprenorphine (which has additional benefit of treating the underlying opioid use disorder), counselling and recovery support, and structured residential treatment for more severe cases. The antidepressant component of the discontinuation syndrome sometimes warrants consideration of a structured antidepressant taper or initiation, depending on the specific clinical picture.

Phuket Island Rehab provides residential addiction medicine treatment in Thailand including medical detox for tramadol and combined tramadol-alcohol dependence, treatment for opioid use disorder, and integrated care for the medical and psychiatric complications. The combined detox is particularly difficult outside of a clinical setting because of the seizure risk and the complex withdrawal pattern; medical supervision is the safe approach.

Summary

Tramadol overdose can produce three potentially co-existing problems that distinguish it from typical opioid overdose: opioid effects (respiratory depression, sedation, miosis, hypotension), seizures (which can occur at relatively modest doses because tramadol lowers the seizure threshold), and serotonin syndrome (with agitation, tremor, clonus, hyperthermia, autonomic instability, particularly with co-administered serotonergic medications). The lethal dose of tramadol alone is generally considered above 3 grams in opioid-naive adults but fatal outcomes have occurred at much lower doses, particularly with alcohol, benzodiazepines, sleeping pills, antidepressants, or other substances. Tramadol is more dangerous than its original marketing suggested because of the seizure risk, the serotonin syndrome risk, the CYP2D6 metaboliser variability, and the underestimated addictive potential. Naloxone reverses the opioid component but does not address seizures or serotonin syndrome. Emergency management includes calling emergency services, supporting breathing, administering naloxone, and managing seizures with benzodiazepines. Heavy drinking combined with tramadol substantially elevates all the overdose risks. As Dr. Ponlawat Pitsuwan summarises, “Tramadol is the opioid people underestimate, and the overdoses we see are different from what the standard opioid teaching prepares clinicians for. The seizures, the serotonin syndrome features, the unexpected severity in CYP2D6 ultra-rapid metabolisers, and the lethal interaction with heavy drinking all combine into a substance that requires more clinical caution than its reputation suggests.”

Frequently asked questions

How much tramadol is an overdose?

Tramadol overdose can occur at doses above the maximum recommended daily dose of 400 mg, with serious overdose typically at doses above 1 gram and lethal outcomes most commonly reported at doses above 3 grams in opioid-naive adults. With other substances in the picture (alcohol, benzodiazepines, opioids, serotonergic medications, sleeping pills), serious or fatal outcomes can occur at much lower doses, including within the prescribed dose range in some scenarios.

Can you die from a tramadol overdose?

Yes. Tramadol overdose can produce fatal respiratory depression, status epilepticus from seizures, severe serotonin syndrome with hyperthermia and rhabdomyolysis, and cardiovascular complications. The risk is substantially elevated when tramadol is combined with alcohol, benzodiazepines, opioids, or serotonergic medications. Reported lethal doses range from less than 1 gram in vulnerable patients with combined ingestions to more than 5 grams in opioid-tolerant patients without other substances.

Does naloxone work for tramadol overdose?

Yes for the opioid component. Naloxone reverses the respiratory depression and the opioid features of tramadol overdose. Naloxone does not reverse the seizure risk or the serotonin syndrome features, which require their own management. The standard dose is 4 mg intranasally (Narcan) or 0.4 to 2 mg by injection, with repeat dosing as needed. Patients given naloxone for tramadol overdose require continued monitoring because the tramadol effects can outlast the naloxone.

What are the signs of tramadol overdose?

Signs include severe drowsiness, slow or shallow breathing, pinpoint pupils, slurred speech, impaired coordination, low blood pressure, and in severe cases unresponsiveness, seizures, hyperthermia, severe tremor, muscle rigidity, and respiratory arrest. The mix of opioid features (sedation, slow breathing, pinpoint pupils) and serotonin syndrome features (agitation, tremor, dilated pupils, sweating, fever) can produce a confusing combined picture.

Can tramadol cause seizures?

Yes. Tramadol lowers the seizure threshold and can cause seizures even at therapeutic doses in vulnerable patients, including patients with prior seizure history, patients on other medications that lower seizure threshold, patients with electrolyte derangement, and patients consuming alcohol. The seizure risk is one of the most distinctive features of tramadol compared with other opioids and is one of the most common reasons for emergency department presentations with the medication.

What is serotonin syndrome from tramadol?

Serotonin syndrome is a potentially fatal condition from excessive serotonergic activity that can develop with tramadol overdose, particularly when other serotonergic medications are also present. Symptoms include agitation, tremor, clonus, hyperreflexia, muscle rigidity, sweating, dilated pupils, fever, and autonomic instability. Severe cases progress to hyperthermia, seizures, and death. The Hunter Criteria are used for diagnosis. Treatment includes discontinuation of serotonergic medications and supportive care.

Sources

• U.S. Drug Enforcement Administration. Tramadol fact sheet. https://www.dea.gov/factsheets/tramadol
• U.S. Food and Drug Administration. Tramadol prescribing information. FDA prescribing information
• U.S. Centers for Disease Control and Prevention (CDC). CDC Clinical Practice Guideline for Prescribing Opioids for Pain. https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm
• National Institute on Drug Abuse (NIDA). Prescription opioids. https://nida.nih.gov/research-topics/prescription-opioids
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Tramadol drug profile. EMCDDA prescription drugs
• Substance Abuse and Mental Health Services Administration (SAMHSA). Medications for opioid use disorder. https://www.samhsa.gov/medications-substance-use-disorders

tramadol, tramadol overdose, Tramal, Zydol, Ultram, Ralivia, Tramadex, Tramacet, Ultracet, opioid, weak opioid, mu-opioid receptor, mu-opioid receptor agonist, partial agonist, O-desmethyltramadol, M1 metabolite, CYP2D6, CYP2D6 ultra-rapid metaboliser, CYP2D6 poor metaboliser, CYP3A4, serotonin reuptake inhibition, noradrenaline reuptake inhibition, SNRI, serotonin syndrome, Hunter Criteria, opioid use disorder, OUD, tramadol use disorder, physical dependence, tolerance, withdrawal, opioid withdrawal, antidepressant discontinuation syndrome, brain zaps, naloxone, Narcan, buprenorphine, Suboxone, methadone, naltrexone, seizure, seizure threshold, status epilepticus, generalised tonic-clonic seizure, bupropion, fluoroquinolone, antipsychotic, theophylline, respiratory depression, sedation, miosis, pinpoint pupils, mydriasis, dilated pupils, hyperthermia, autonomic instability, clonus, hyperreflexia, muscle rigidity, rhabdomyolysis, QT prolongation, torsades de pointes, alcohol, alcohol use disorder, AUD, heavy drinking, benzodiazepine, Xanax, Valium, Ativan, Klonopin, sleeping pill, Ambien, gabapentin, pregabalin, SSRI, SSRIs, sertraline, fluoxetine, paroxetine, escitalopram, venlafaxine, duloxetine, MAOI, phenelzine, tranylcypromine, linezolid, methylene blue, triptan, lithium, St John’s wort, cyproheptadine, lorazepam, midazolam, diazepam, FDA, DEA, NIDA, SAMHSA, CDC, EMCDDA, Schedule IV, controlled substance, Phuket Island Rehab.